pain after shingles postherpetic neuralgia
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Aged 18 years or older. - Diagnosed by a physicians with a herpes zoster skin rash. - Pain in the dermatomes involved in the original eruption of herpes zoster. - Able and willing to give written informed consent
Exclusion criteria
Exclusion criteria: - Patients with previous neurolytic or neurosurgical treatment for PHN. (Radiofrequency treatment of the DRG is allowed). - Patients receiving pain treatment by topical capsaicin 8% in the last 6 months - Patients who have other types of pain, which could confound the assessment of the neuropathic pain due to PHN. - Patients with polyneuropathy or severe other neurologic disease that might affect outcome measures. - Patients with skin conditions in the area affected by the neuralgia that could alter sensation. - Patients with major cognitive or psychiatric disorders. - Problems with communication (language, deafness, aphasia etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters/endpoints: The main study parameters are immunological and metabolic parameters in plasma and CSF, skin nerve fiber density measurements, questionnaires, and QST. We will determine whether the addition of these main study parameters identifies other/additional clinical phenotypes than those identified with QST alone and with which minimal parameter datasets these subsets can be identified. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint is effect of standard pain treatment for PHN within patient groups with the different clinical phenotypes expressed as decrease in numeric rating scale (NRS), global perceived effect (GPE), time to treatment effect, regain of function, quality of life and improvement of QST parameters assessed at one year follow up. Spinal immunological parameters and metabolites will be assessed with MRS in a subset of patients who provided additional informed consent. Individual methadone metabolism is assessed by determining CYP2B6 enzyme polymorphisms. | — |
Countries
Netherlands
Outcome results
None listed